Q1 2025 Elanco Animal Health Inc Earnings Call Transcript
Key Points
- Elanco Animal Health Inc (ELAN) exceeded first-quarter guidance for revenue, adjusted EBITDA, and adjusted EPS, marking the seventh consecutive quarter of underlying growth.
- The company reported 4% organic constant currency revenue growth, driven by both price and volume increases.
- Elanco raised its full-year expectations for new product revenue to $660 million to $740 million, with strong performance from recently launched products like Credelio Quattro.
- The company is deleveraging faster than planned, improving its net leverage target for year-end to 3.9 to 4.3 times, aided by strong working capital performance and favorable currency impacts.
- Elanco's innovation strategy is yielding results, with $198 million in first-quarter revenue from new products and a robust pipeline, including the anticipated IL-31 approval in late 2025.
- The US retail business faced challenges, with a 21% decline in the first two months of the year due to cooler weather impacting consumer spending.
- Elanco is exposed to potential tariff impacts, estimating a $16 million to $20 million negative impact on adjusted EBITDA for 2025, primarily due to US-China tariffs.
- The company is maintaining its full-year adjusted EBITDA and EPS guidance despite macroeconomic uncertainties and potential tariff risks.
- Operating expenses increased by 3% year-over-year, driven by investments in product launches and R&D, impacting short-term profitability.
- The international farm animal business faced headwinds from the Echstone recall and commercial model changes, creating a 4% point headwind to year-over-year growth.
Ladies and gentlemen, thank you for standing by. Welcome to Elanco Animal Health's first-quarter 2025 earnings conference call.
At this time, all lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. (Operator Instructions)
Thank you. I would now like to hand the call over to Tiffany Kanaga, Head of Investor Relations. You may begin your conference.
Good morning. Thank you for joining us for our Elanco Animal Health first-quarter 2025 earnings call. I'm Tiffany Kanaga, Vice President of Investor Relations and ESG. Joining me on today's call are Jeff Simmons, our President and Chief Executive Officer; Todd Young, our Chief Financial Officer; and Beth Haney from Investor Relations. The slides referenced during this call are available on the investor relations section of Elanco.com. Today's discussion will include forward-looking statements. These statements are based on our current assumptions
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
